Maxim Group downgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Buy to Hold.Analyst Jason McCarthy highlighted:IMUC reported 3Q16 with a net loss ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE